ICLs effective over long-periods

Article

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

Kazutaka Kamiya, MD, PhD and colleagues from the University of Kitasato School of Medicine and Sanno Hospital, Tokyo, Japan conducted a study to determine the long-term clinical outcomes of implantation of a biocompatible collagen copolymer lens (Visian ICL, STAAR Surgical) in patients with high to moderate myopia. A total of 56 eyes (34 patients) with myopic refractive errors of -4 to -15.25 D received the lens and follow-up examinations were conducted 1, 3 and 6 months and 1, 2 and 4 years following surgery.

At four years postoperative, 79% of eyes were within ±0.5 D of target refraction and 93% were within ±1 D of target refraction. Mean manifest changes in refraction of -0.24 D occurred from 1 month to 4 years and no vision-threatening complications were observed.

The results of this study suggest that ICLs are safe and effective and can offer stable refractive results even over long time periods making them a suitable treatment option for eyes with moderate to high myopia.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.